Biosyent Inc
- LAST PRICE11.2000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots10.9000/ 100
- Ask / Lots11.3500/ 600
- Open / Previous Close--- / 11.2000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RX |
|---|---|---|
| 09:32 ET | 100 | 10.91 |
| 10:24 ET | 100 | 11.24 |
| 10:26 ET | 400 | 11.25 |
| 10:45 ET | 100 | 11.25 |
| 12:17 ET | 200 | 11.24 |
| 02:12 ET | 900 | 11.25 |
| 04:00 ET | 100 | 11.2 |
Nov 20, 2024
BioSyent Releases Financial Results for Q3 and YTD 2024, from 8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 20, 2024 by Dow JonesBioSyent Declares Fourth Quarter 2024 Dividend, from 7:55AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:55AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 13, 2024
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024, from 4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biosyent Inc | 133.3M | 18.7x | +6.22% |
Arch Biopartners Inc | 119.6M | -47.2x | --- |
Spectral Medical Inc | 147.1M | -5.6x | --- |
Innocan Pharma Corp | 60.0M | -16.2x | --- |
LSL Pharma Group Inc | 46.8M | -19.0x | --- |
1CM Inc | 29.4M | -53.0x | --- |
Company Information
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
Contact Information
- Headquarters
- 2476 Argentia Road, Suite 402MISSISSAUGA, ON, Canada L5N 6M1
- Phone
- 905-206-0013
- Fax
- 905-206-1413
Executives
- Chairman of the Board, President, Chief Executive Officer
- Rene Goehrum
- Vice President, Corporate Development
- Robert March
- Vice President- Corporate Development
- Joost Van Der Mark
- Vice President - Community Health Business
- Kevin Wilson
- Director - Human Resources
- Neelu Atwal
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $132.1M |
|---|---|
Revenue (TTM) | $33.8M |
Shares Outstanding | 11.8M |
Dividend Yield | 1.61% |
Annual Dividend Rate | 0.1800 CAD |
Ex-Dividend Date | 11-29-24 |
Pay Date | 12-16-24 |
Beta | 0.91 |
EPS | $0.60 |
Book Value | $2.96 |
P/E Ratio | 18.7x |
Price/Sales (TTM) | 3.9 |
Price/Cash Flow (TTM) | 17.3x |
Operating Margin | 24.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
